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Abstract 
Pancreatic cancer remains as one of the most deadly cancers, and responds poorly to 
current therapies. The prognosis is extremely poor, with a 5-year survival of less than 
5%. Therefore, search for new effective therapeutic drugs is of pivotal need and 
urgency to improve treatment of this incurable malignancy. Synthetic alkyl-
lysophospholipid analogues (ALPs) constitute a heterogeneous group of unnatural 
lipids that promote apoptosis in a wide variety of tumor cells. In this study, we found 
that the anticancer drug edelfosine was the most potent ALP in killing human 
pancreatic cancer cells, targeting endoplasmic reticulum (ER). Edelfosine was taken up 
in significant amounts by pancreatic cancer cells, and induced caspase- and 
mitochondrial-mediated apoptosis. Pancreatic cancer cells show a prominent ER, and 
edelfosine accumulated in this subcellular structure, inducing a potent ER stress 
response, with caspase-4, BAP31 and c-Jun NH2-terminal kinase (JNK) activation, 
CHOP/GADD153 upregulation, and phosphorylation of eukaryotic translation initiation 
factor 2 α-subunit (elF2α), that eventually led to cell death. Oral administration of 
edelfosine in xenograft mouse models of pancreatic cancer induced a significant 
regression in tumor growth, and an increase in apoptotic index, as assessed by TUNEL 
assay and caspase-3 activation in the tumor sections. The ER stress-associated 
marker CHOP/GADD 153 was visualized in the pancreatic tumor isolated from 
edelfosine-treated mice, indicating a strong in vivo ER stress response. These results 
suggest that edelfosine exerts its proapoptotic action in pancreatic cancer cells, both in 
vitro and in vivo, through its accumulation in the ER, which leads to ER stress and 
apoptosis. Thus, we propose that endoplasmic reticulum could be a key target in 
pancreatic cancer, and edelfosine may constitute a prototype for the development of a 
new class of antitumor drugs targeting endoplasmic reticulum. 
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Introduction 
Pancreatic adenocarcinoma is one of the most aggressive cancers. Pancreatic cancer 
is often detected at an advanced stage and prognosis is extremely poor, with a median 
survival of 4-6 months (Li et al., 2004). It represents ~10% of all gastrointestinal 
malignancies (Neoptolemos et al., 2003), and it is the fourth most common cause of 
death in Western countries (Jemal et al., 2007). Most patients with diagnosed 
pancreatic cancer do not benefit from surgery and frequently need palliative 
chemotherapy (van Riel et al., 1999). Standard treatments for advanced disease 
include 5-fluorouracil and gemcitabine. However, even gemcitabine, considered the 
gold standard for pancreas cancer, has a response rate of less than 20% (Li et al., 
2004).  
The endoplasmic reticulum (ER) is an organelle responsible for several 
important cellular functions, including protein and lipid biosynthesis, post-translational 
modification, folding and assembly of newly-synthesized secretory proteins and cellular 
calcium store. Various conditions can disturb ER functions, leading to a series of 
events collectively termed ER stress. An excessive ER stress leads to an accumulation 
of misfolded proteins in the ER lumen, that initiates the unfolded protein response 
(UPR) to restore normal ER function. However, persistent ER stress can switch the 
cytoprotective functions of UPR into cell death promoting mechanisms, leading to the 
triggering of ER-dependent apoptotic cascades. One of the features of pancreatic cells 
is a highly developed ER, apparently due to a heavy engagement in insulin secretion 
(Oyadomari et al., 2002). ER stress is directly related to pancreatic cell dysfunction and 
death by apoptosis, during the progression of type 1 and type 2 diabetes mellitus and 
Wolfram syndrome (Fonseca et al., 2009). Nevertheless, ER stress sensors do not 
directly cause cell death, but rather initiate the activation of downstream molecules 
such as CHOP (C/EBP homologus protein)/growth arrest and DNA damage-inducible 
gene 153 (GADD153) or c-Jun NH2-terminal kinase (JNK), which further push the cell 
down the path of death. Three main pathways of ER stress-induced apoptosis are 
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known: 1) upregulation of the transcription factor CHOP/GADD153 (Ron and Habener, 
1992); 2) JNK activation (Urano et al., 2000); 3) activation of caspase-12 in murine 
systems or caspase-4 in human cells (Hitomi et al., 2004). These three pathways all 
end in caspase cascade activation followed by the induction of apoptosis. 
Accumulation of unfolded proteins, leading to ER stress, can be induced by 
anticancer chemotherapeutic agents such as bortezomib (Fribley et al., 2004), 
geldanamycin (Mimnaugh et al., 2004), cisplatin (Mandic et al., 2003), and 
cannabinoids (Carracedo et al., 2006). Also, chronic exposure to long-chain free fatty 
acids induces ER stress and cell death in pancreatic beta-cells (Cunha et al., 2008). 
Synthetic alkyl-lysophospholipid analogues (ALPs) are a novel class of unnatural lipids 
with promising anticancer activity, including clinically relevant drugs such as 
miltefosine, perifosine and erucylphosphocholine, that act at the cell membrane level 
(Gajate and Mollinedo, 2002; Mollinedo et al., 2004). Edelfosine (1-O-octadecyl-2-O-
methoxy-rac-glycero-3-phosphocholine, ET-18-OCH3), considered the ALP prototype 
compound, has been shown to induce apoptosis in malignant cells in a rather selective 
way, through the involvement of lipid rafts and ER (Gajate et al., 2004; Gajate et al., 
2000b; Gajate et al., 2009a; Gajate and Mollinedo, 2001; Gajate and Mollinedo, 2007; 
Mollinedo et al., 1997; Mollinedo and Gajate, 2006; Mollinedo and Gajate, 2010; Nieto-
Miguel et al., 2007). 
Because pancreatic cancer cells show prominent ER (Klimstra et al., 1992; 
Skarda et al., 1994), we wondered whether edelfosine might be active against 
pancreatic cancer by targeting ER. Hence, we investigated the in vitro and in vivo 
action of edelfosine on pancreatic cancer as well as its mechanism of action. In this 
work, using different in vitro and in vivo experimental approaches, we show that 
edelfosine behaves as an effective anticancer agent that induces apoptotic cell death 
of pancreatic cancer cells, via accumulation of the drug at the ER, leading to ER stress 
response and eventually to apoptosis. 
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Results 
Induction of apoptosis by edelfosine and other ALPs in human pancreatic cancer cells 
We have recently found that the pharmacologically relevant concentration in plasma of 
edelfosine ranges between 10-20 μM (Estella-Hermoso de Mendoza et al., 2009; 
Mollinedo et al., 2010). Thus, we first analyzed the proapoptotic activity of edelfosine 
and different ALPs, including perifosine, miltefosine, and erucylphosphocholine 
(ERPC), at 10 and 20 μM, on a number of human pancreatic cancer cells. Our data 
indicated that edelfosine induced cell death in a dose- and time-dependent manner 
(Figure 1a). We found that edelfosine was the only ALP that promoted apoptosis at 10 
μM in all pancreatic cancer cells (Figure 1a), whereas the other ALPs did not induce 
cell killing at this drug concentration, even after 72 h incubation (data not shown). At 20 
μM, we found that ALPs ranked edelfosine > perifosine >> ERPC ≥ miltefosine in their 
capacity to induce apoptosis in the pancreatic BxPC-3, Capan-2, CFPAC-1 and HuP-
T4 cancer cells (Figure 1b). We included in our analysis the structurally related inactive 
edelfosine analogue 1-O-octadecyl-rac-glycero-3-phosphocholine (ET-18-OH) (Gajate 
et al., 1998; Mollinedo et al., 1997), in which the methoxy group in the sn-2 position 
was replaced by an OH group. We found that, save edelfosine and perifosine, the other 
ALP analogues rendered similar figures of apoptosis as ET-18-OH (Figure 1b). Thus, 
edelfosine and perifosine were the only ALPs with proapoptotic activity against 
pancreatic cancer cells.  
 
Edelfosine accumulates in the ER of pancreatic cancer cells  
Because edelfosine behaved as the most potent ALP in inducing cell death in 
pancreatic cancer cells, we next analyzed its mechanism of action. First, we found that 
that all pancreatic cancer cell lines assayed incorporated high amounts of drug (Figure 
1c). Next, we found that the new fluorescent edelfosine analogue Et-BDP-ET (1-O-[11'-
(6''-ethyl-1'',3'',5'',7''-tetramethyl-4'',4''-difluoro-4''-bora-3a'',4a''-diaza-s-indacen-2''-
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yl)undecyl]-2-O-methyl-rac-glycero-3-phosphocholine) (Mollinedo et al., 2011) 
accumulated in the ER of HuP-T4 and Capan-2 cells (Figure 2a), as assessed using a 
version of RFP targeted to ER lumen (erRFP; endoplasmic reticulum-targeted red 
fluorescence protein), which completely colocalized with the ER marker calreticulin 
(Klee and Pimentel-Muinos, 2005). Incorporation of fluorescent Et-BDP-ET into the 
cells was blocked by adding the parent drug edelfosine (data not shown), thus 
behaving as a reliable edelfosine fluorescent analogue to visualize the subcellular 
location of the drug “in situ”. 
 
Edelfosine induces ER stress response in pancreatic cancer cells  
We next analyzed whether this drug induced an ER stress response leading to 
apoptosis in HuP-T4 cells. To this aim, we examined the effect of edelfosine on a 
number of ER stress-associated markers, including caspase-4, CHOP/GADD153, 
BAP31, GRP78/BiP and eukaryotic translation initiation factor 2 α-subunit (elF2α). 
Human caspase-4 is a potential homologue of murine caspase-12 involved in ER 
stress (Hitomi et al., 2004). As shown in Figure 2b, edelfosine treatment induced 
caspase-4 activation, as assessed by cleavage of procaspase-4 into the 20-kDa active 
form. CHOP/GADD153 activates transcription of several genes that potentiate 
apoptosis during ER stress (Oyadomari and Mori, 2004). CHOP/GADD153 expression, 
together with phosphorylation of eIF2α, were strongly induced in HuP-T4 cells following 
edelfosine treatment (Figure 2b). BAP31 is an integral membrane protein of the ER that 
regulates ER-mediated apoptosis through its caspase-8-mediated cleavage into a 20-
kDa fragment, which directs proapoptotic signals between ER and mitochondria 
(Breckenridge et al., 2003). Here, we found that BAP31 was cleaved into the p20 
fragment upon edelfosine treatment (Figure 2b). Edelfosine did not upregulate 
Grp78/BiP (Figure 2b), a major ER chaperone that binds Ca2+ and promotes tumor 
proliferation, survival, metastasis, and resistance to a wide variety of therapies (Li and 
Lee, 2006). ER stress has been shown to induce activation of Bax (Zong et al., 2003), 
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and we found Bax activation in response to edelfosine treatment in pancreatic cancer 
cells, by using an anti-Bax monoclonal antibody that recognized the active form of Bax 
(Figure 2b). Previous studies have shown that ASK1-mediated JNK activation is crucial 
for ER-induced apoptosis (Nishitoh et al., 2002). We found here that edelfosine 
induced a potent and sustained activation of JNK in all pancreatic cancer cells lines 
(Figure 2c). Pre-incubation with the caspase-4 inhibitor z-LEVD-fmk, or the specific 
JNK inhibitor SP600125, diminished edelfosine-induced apoptosis (Figure 2, d and e), 
when used at concentrations that prevented edelfosine-induced caspase-4 and JNK 
activation (data not shown). These data reveal that edelfosine accumulates in the ER 
of pancreatic cancer cells, and induces an ER stress response. 
 
Edelfosine induces sXBP1 expression 
When the UPR is induced during ER stress, the ER-resident transmembrane 
kinase/RNase inositol-requiring enzyme 1 (IRE1) is activated, leading to site-specific 
splicing to form spliced XBP1 mRNA (sXBP1) by removing a 26-nucleotide internal 
sequence from unspliced XBP1 (uXBP1) mRNA. The presence in this 26-nucleotide 
fragment of a PstI restriction site further allowed us to distinguish between both forms 
by restriction analysis of PCR-amplified cDNA, and thus to assay for ER stress 
response activation (Hirota et al., 2006). By RT-PCR we found the induction of sXBP1 
mRNA following treatment of BxPC-3 cells with 20 μM edelfosine (Figure 3a). Similar 
data were obtained by PstI restriction analysis (data not shown). Because sXBP1 is a 
key modulator of the UPR, our results suggest that edelfosine induces ER stress and 
UPR signaling in pancreatic cancer cells.      
UPR is known as a prosurvival response to reduce the accumulation of 
unfolded proteins and restore normal ER function. However, when persistent, ER 
stress can switch the cytoprotective functions of UPR into cell death promoting 
mechanisms. Preincubation of BxPC-3 cells for 1 h with different concentrations (up to 
2 mM) of dithiothreitol (DTT), a widely-used ER and UPR stress inducer, before 
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edelfosine addition, did not cause apoptosis (Supplementary Figure S1a). Pretreatment 
of BxPC-3 cells with DTT for 1 h, followed by washing off DTT and subsequent 
incubation with edelfosine for 24 h slightly reduced the percentage of apoptotic cells as 
compared with cells treated only with edelfosine without DTT pretreatment 
(Supplementary Figure S1a). However, this reduction was not statistically significant (P 
= 0.15). 
By using the primers indicated in Supplementary data, the sXBP1 form 
generates a 414 bp fragment, while the uXBP1 form generates a 440-bp fragment, 
which contains a PstI restriction site leading to the generation of two bands of 294 and 
146 bp following PstI digestion. However, sXBP1, lacking the restriction site is resistant 
to PstI digestion, and hence only one band of 414 bp is obtained.  As shown in 
Supplementary Figure S1b, sXBP1 was readily observed in pancreatic cancer cells 
incubated with DTT, edelfosine, or DTT+edelfosine. Edelfosine by itself was a potent 
inducer of sXBP1 (Supplementary Figure S1b). These results suggest that edelfosine 
activates UPR by activating the IRE1-XBP1 branch of the UPR pathway. Taken 
together, our data might suggest that previous induction of UPR does not inhibit 
edelfosine-induced apoptosis. Thus, our data suggest that edelfosine action on ER is 
persistent and leads to the triggering of apoptotic signals that may overcome protective 
UPR mechanisms. 
 
Edelfosine induces changes in ER calcium level 
Because ER plays a critical role in controlling cellular Ca2+ levels, we next analyzed 
how edelfosine affected [Ca2+]ER. Reconstitution of ER-targeted aequorin with a 
semisynthetic prosthetic group, coelenterazine n, required previous depletion of Ca2+ of 
the ER to prevent aequorin consumption during reconstitution (Montero et al., 1997b). 
Once aequorin was reconstituted, the ER was refilled again with Ca2+ by perfusing the 
cells with extracellular medium containing 1 mM Ca2+. This led to an increase in 
[Ca2+]ER, that reached a steady-state of around 250 µM within 3-4 min in BxPc-3 cells 
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(Figure 3a). Addition of edelfosine induced a large increase in [Ca2+]ER, which nearly 
doubled the previous values within 10-15 min (Figure 3a). This effect was time 
dependent. Adding edelfosine 15 min before starting ER refilling induced a huge 
[Ca2+]ER increase reaching levels above 900 µM (Figure 3b). However, longer 
incubation times (30 and 60 min) with edelfosine induced only a two-fold increase of 
the steady-state ER calcium levels (Figure 3b). These results suggest a progressive 
decrease in the ability of the ER to take up Ca2+, and therefore these data could 
indicate that edelfosine affects one of the major functions of the ER, by altering the ER 
calcium level in a time-dependent way, which could have consequences in the cell’s 
fate. Thus, edelfosine affects a number of ER-related processes and functions.    
 
Involvement of caspases 8 and 10, and cleavage of Bid in edelfosine-induced 
apoptosis 
BAP31 cleavage by edelfosine (Figure 2b) suggested the involvement of caspase-8 in 
the process. Western blot analyses showed early cleavage of procaspases 8 and 10 in 
pancreatic cancer cells after edelfosine treatment, as assessed by the appearance of 
p18 active caspase-8 and p23 active caspase-10 forms (Figure 4a). Preincubation of 
cells with caspase-8 inhibitor z-IETD-fmk and caspase-10 inhibitor z-AEVD-fmk 
blocked edelfosine-induced apoptosis (Figure 4b). Thus, both caspases 8 and 10 are 
involved in the apoptosis response induced by edelfosine in pancreatic cancer cells. 
Bid is a potent proapoptotic Bcl-2 family member which, upon proteolytic 
activation by caspases 8 or 10, translocates onto mitochondria to promote activation of 
the Bax/Bak subgroup of the apoptotic Bcl-2 family proteins, and thereby contributes to 
the release of cytochrome c (Kuwana et al., 2005). We found Bid cleavage after 
edelfosine treatment, by using an anti-Bid antibody that recognizes both full-length and 
18-kDa cleaved forms (Figure 4c). These results suggested that Bid might play a role in 
edelfosine-induced apoptosis by transferring signals to mitochondria.     
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Involvement of mitochondria in edelfosine-induced apoptosis in human pancreatic 
cancer cells  
Because the above results showed that edelfosine promoted the cleavage of BAP31 
and Bid into p20 and p18 fragments, acting as transmitters towards mitochondria in 
apoptosis signaling, we next analyzed the role of mitochondria in the apoptotic 
response triggered by edelfosine in pancreatic cancer cells. Once cytochrome c is 
released from mitochondria to the cytosol during apoptosis, it leads to formation of the 
apoptotic protease-activating factor-1 (Apaf-1)/Caspase-9 complex, initiating an 
apoptotic protease cascade that promotes degradation of key structural proteins, 
including poly(ADP-ribose) polymerase (PARP), causing DNA fragmentation and 
apoptosis. We found that edelfosine induced caspase-9, -7 and -3 activation, assessed 
by cleavage of procaspase-9, -7, and -3 into their respective active forms, as well as 
proteolysis of the caspase-3 and caspase-7 substrate poly(ADP-ribose) polymerase 
(PARP) in all pancreatic cancer cells assayed (Figure 5a). The caspase-9 inhibitor z-
LEHD-fmk, and the caspase-3 inhibitor Ac-DEVD-CHO, inhibited the apoptotic death of 
pancreatic cancer cells induced by edelfosine (Figure 5b). In addition, inhibition of 
caspases by the broad caspase inhibitor z-VAD-fmk completely abrogated edelfosine-
induced apoptosis (Figure 5b). These findings indicate that edelfosine-induced 
apoptosis in human pancreatic cancer cells is caspase-dependent. 
As shown in Figure 5c, edelfosine treatment induced a marked release of 
cytochrome c from the mitochondria to the cytosol in BxPC-3 pancreatic cancer cells. 
Similarly, we also found mitochondrial cytochrome c release in Capan-2, CFPAC-1 and 
HuP-T4 pancreatic cancer cells following edelfosine treatment (Supplementary Figure 
S2). Because Bcl-xL acts as a safeguard of mitochondria, preventing cytochrome c 
release and apoptosis, we stably transfected BxPC-3 cells with pSFFV-bcl-xL plasmid 
(BxPC-3-Bcl-XL), containing the human bcl-xL open reading frame, or with control 
pSFFV-Neo plasmid (BxPC-3-Neo). BxPC-3-Neo cells behaved similarly as non-
transfected BxPC-3 cells regarding all parameters studied. BxPC-3-Neo cells 
 10
expressed a small level of endogenous Bcl-XL, whereas a high expression of this 
protein was observed in BxPC-3-Bcl-XL cells (Figure 5d). While BxPC-3-Neo cells 
underwent apoptosis after treatment with edelfosine, Bcl-XL overexpression prevented 
edelfosine-induced apoptosis (Figure 5e). Edelfosine induced mitochondrial release of 
cytochrome c in BxPC-3-Neo cells (Figure 5f), but cytochrome c release was highly 
diminished in BxPC-3-Bcl-XL cells (Figure 5f). These data show that mitochondria are 
involved in edelfosine-induced pancreatic cancer cell death. 
 
In vivo antitumor effect of edelfosine in a pancreatic cancer xenograft model      
We next evaluated the effect of orally administered edelfosine in two pancreatic cancer 
xenograft animal models. Following toxicity analyses with CB17-severe combined 
immunodeficient (CB17-SCID) and BALB/c mice (data not shown), we found that a 
daily oral administration dose of 30 mg/kg edelfosine was well tolerated, 45 mg/kg 
being the maximum tolerated dose. CB17-SCID mice were inoculated with 5 x 106 
Capan-2 or HuP-T4 cells. When appreciable tumors were observed in the two 
pancreatic cancer animal models, mice were randomly assigned to cohorts of 8 mice 
each, receiving a daily oral administration of edelfosine (30 mg/kg) or an equal volume 
of vehicle (water). Serial caliper measurements were done every 3 days to calculate 
tumor volume until mice were sacrificed (Figure 6a). A comparison of tumors isolated 
from untreated control and drug-treated Capan-2 or HuP-T4-bearing mice, at the end of 
the treatment, rendered a remarkable anti-pancreatic cancer activity of edelfosine 
(Figure 6, b and c), with a statistically significant (P < 0.05) reduction of ~57% and 
~66% in the tumor weight in both Capan-2  (233 ± 50 mg vs. 539 ± 106 mg, for 
edelfosine-treated vs. untreated mice, n = 8) and HuP-T4 (305 ± 67 mg vs. 896 ± 97 
mg, for edelfosine-treated vs. untreated mice, n = 8) animal models (Figure 6b). 
Likewise, a statistically significant (P < 0.05) reduction of ~60% and ~72 % in tumor 
volume was also detected in both Capan-2 (240 ± 48 mm3 vs. 600 ± 124 mm3, for 
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edelfosine-treated vs. untreated mice, n = 8) and HuP-T4 (312 ± 68 mm3 vs. 1114 ± 
145 mm3, for edelfosine-treated vs. untreated mice, n = 8) animal models (Figure 6b). 
Interestingly, while tumors from drug-free mice showed a highly vascular appearance, 
tumors from edelfosine-treated mice were pale and poorly vascularized (Figure 6c). 
Organ examination at necropsy did not reveal any apparent toxicity (data not shown), 
and no significant differences in mean body weight were detected between drug-
treated and drug-free control animals (2-3% of body weight loss in the drug-treated vs. 
drug-free control groups). 
 
In vivo identification of apoptosis and ER stress in pancreatic tumors following 
edelfosine oral treatment  
Histological patterns of tumors isolated from control drug-free tumor-bearing animals 
revealed a relative uniformity in cell size and morphology (Figure 7a). In contrast, 
examination of hematoxylin and eosin (H&E)-stained sections of tumors from mice 
orally treated with edelfosine showed the presence of irregular, large and medium-
sized giant cells with eosinophilic cytoplasm. The nuclei in dying cells were either 
pyknotic or displayed nuclear fragmentation characteristic of cell death by apoptosis 
(Figure 7a). Induction of apoptosis was further supported by performing TUNEL 
apoptosis assay in tumor sections. No TUNEL fluorescence intensity expression was 
found in the tumor xenografts of the control drug-free group (Figure 7b). However, a 
strong TUNEL-positive signal, indicating apoptotic cells, was detected in the 
edelfosine-treated group (Figure 7b). Our data showed a significant difference in the 
percentage of TUNEL-positive cells between control drug-free and drug-treated groups, 
namely 2.2 ± 0.6 % vs. 35.0 ± 5.4 %.  
 The anti-activated caspase-3 specific antibody selectively labeled the 
cytoplasm of cells that had a morphology consistent with apoptosis in tumors from 
drug-treated mice (Figure 7c), while lack of staining was observed in control drug-free 
group. Our data showed that the caspase-3 labeling index in the tumor tissue of the 
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drug-treated mice was significantly higher (40 ± 5.6 %) than that in the drug-free mice 
(1.2 ± 0.1 %) (Figure 7c).  
Interestingly, the ER stress-associated marker CHOP/GADD153 was visualized 
by immunohistochemistry in the nuclei of cells in the pancreatic tumor isolated from 
edelfosine-treated mice, indicating a strong ER stress response in the tumor sections. 
However, CHOP/GADD153 staining was absent in tumors derived from control drug-
free mice (Figure 7d). 
 
Discussion 
Pancreatic adenocarcinoma responds poorly to current therapies and remains as an 
incurable malignancy. This makes this tumor especially challenging for searching novel 
effective anticancer drugs. Our in vitro and in vivo data indicate that edelfosine is a 
potent antitumor agent against pancreatic tumor cells, and highlight the importance of 
ER as a target for the treatment of pancreatic cancer. We have found that edelfosine 
behaves as the most potent ALP in killing human pancreatic cancer cells by targeting 
ER. Perifosine was also active against pancreatic cancer cells, but other ALPs, such as 
miltefosine and erucylphosphocholine, as well as the structurally related inactive 
molecule ET-18-OH, failed to induce death cell in these cells, underlining the 
importance of the molecular structure of edelfosine for its anti-pancreatic cancer 
activity. The studies reported here show for the first time in vitro and in vivo evidences 
for the induction of ER stress in the mechanism of action of an ER-targeted antitumor 
drug in pancreatic cancer, suggesting that this could be a promising therapeutic 
approach in the treatment of pancreatic cancer. 
We have found evidence that edelfosine was working in vivo in a similar manner 
to that observed in vitro. Oral administration of edelfosine showed a remarkable in vivo 
antitumor and proapoptotic activity, promoting a potent apoptosis response in human 
tumor xenografts in SCID mice, as assessed by morphological changes, TUNEL assay 
and caspase-3 activation. Our present data represent the first demonstration of the in 
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vivo proapoptotic activity of edelfosine, which further support the notion that the 
antitumor action of this ALP highly depends on its ability to promote apoptosis in 
tumors. Edelfosine treatment led to dramatic tumor regression in pancreatic tumor 
animal models, and tumors became smaller and poorly vascularized, which could be in 
agreement with reports showing an antiangiogenic effect of edelfosine (Zerp et al., 
2008). 
Pancreatic cancer cells have been reported to show prominent ER (Klimstra et 
al., 1992; Skarda et al., 1994). Here, we report for the first time that edelfosine 
accumulates in the ER of human pancreatic cancer cells and triggers a prolonged ER 
stress response, leading to apoptosis. Unlike several anticancer drugs that induce ER 
stress in an indirect way, here we found that edelfosine accumulates in the ER of 
human pancreatic cancer cells, and promotes a number of changes in ER-regulated 
homeostatic processes, leading to the triggering of sundry ER-derived apoptotic events 
that eventually converge on the mitochondria. Edelfosine also upregulates sXbp1, a 
key modulator of the UPR, but activation of this protective response during ER stress 
seems not to be enough to prevent apoptosis. The role of UPR activation in edelfosine-
induced apoptosis remains to be elucidated, and we cannot rule out that upregulation 
of the above UPR marker might merely be a correlative phenomenon. The results 
obtained measuring the effects of edelfosine on [Ca2+]ER in BxPc-3 cells suggest that 
edelfosine induces a significant deregulation of global Ca2+ homeostasis. We have 
previously shown that edelfosine increases cytosolic [Ca2+] in HeLa cells (Nieto-Miguel 
et al., 2007). On these grounds, and taking into account the interaction of edelfosine 
with cell membranes and lipids (Ausili et al., 2008; Busto et al., 2008; Busto et al., 
2007; Gajate et al., 2004; Gajate et al., 2009a; Gajate et al., 2009b; Mollinedo et al., 
2010; Mollinedo and Gajate, 2006; Torrecillas et al., 2006; Zaremberg et al., 2005), it 
might be envisaged that the increase in cytosolic [Ca2+] could be due to an increased 
permeability of the plasma membrane, resulting in Ca2+ entry from the extracellular 
medium, which it then leads to the herein reported increase in [Ca2+]ER, well above the 
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steady state levels in control cells. The effect on [Ca2+]ER may seem puzzling, because 
ER stress has been rather associated with ER-stored Ca2+ release. However, our 
present results also indicate that this Ca2+ pumping into the ER, following edelfosine 
incubation, is progressively decreased with time. These results might reflect an altered 
function of the ER, leading to a gradual impairment in its capacity to take up Ca2+, and 
hence to Ca2+ homeostasis deregulation in the ER. All these aspects deserve further 
studies on the role of Ca2+ in the proapoptotic action of edelfosine in pancreatic cancer 
cells. 
Figure 8 depicts a model for the involvement of ER in edelfosine-induced 
apoptosis in pancreatic cancer cells. Our previous (Nieto-Miguel et al., 2007) and 
present data suggest that edelfosine causes a gradual alteration in calcium 
homeostasis. Transient increase in cytosolic Ca2+ stimulates Ca2+ uptake by 
mitochondria (Rizzuto and Pozzan, 2006), which contributes to mitochondrial 
membrane permeability transition, releasing apoptogenic proteins. Here, we have 
found that edelfosine induces cytochrome c release from mitochondria in pancreatic 
cancer cells. Cytochrome c released from mitochondria binds to Apaf-1 and 
procaspase-9 to form the so-called apoptosome (Riedl and Salvesen, 2007). This 
complex catalyzes the activation of caspases that executes the apoptotic cell death 
program. The herein reported abrogation of edelfosine-induced apoptosis, and 
mitochondrial cytochrome c release, by Bcl-XL overexpression indicates an essential 
role for mitochondria in the induction of apoptosis by this anticancer drug in pancreatic 
cancer cells. ER stress-induced processing of procaspase-9 can also occur in the 
absence of cytochrome c release and in Apaf-1-null fibroblasts (Rao et al., 2002), 
suggesting that caspase-4 can directly trigger caspase-9 activation and apoptosis 
independently of the mitochondrial cytochrome c/Apaf-1 pathway, at least in certain cell 
types. Our results suggest that both caspase-4- and apoptosome-mediated signaling 
pathways are involved in edelfosine-induced apoptosis (Figure 8).  A prolonged ER 
stress during exposure to edelfosine leads to the induction of a proapoptotic 
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transcription factor, CHOP/GADD153. Here, we found both in vitro and in vivo evidence 
for the upregulation of CHOP/GADD153 following edelfosine treatment in pancreatic 
cancer cells, whereas the level of GRP78/BiP protein was not significantly altered, 
tipping the balance in favor of an ER stress-induced cell death. Thus, these results 
imply that induction of CHOP/GADD153 expression is closely associated with the 
progression of apoptosis during exposure of pancreatic cancer cells to edelfosine. Our 
data suggest that edelfosine induces in pancreatic cancer cells the cleavage of BAP31, 
an integral membrane protein of the ER, with the formation of p20 fragment that directs 
proapoptotic signals between ER and mitochondria, resulting in the discharge of Ca2+ 
from the ER and its concomitant uptake into the mitochondria. Also, edelfosine 
promotes phosphorylation of eIF2α, another typical response to ER stress. In addition, 
we found that ER stress-associated caspase-4 was activated before the onset of 
apoptosis following edelfosine treatment in pancreatic cancer cells. Caspase-4 
inhibition abrogated edelfosine-induced apoptosis, suggesting that caspase-4 is 
required for the triggering of cell death. In addition, edelfosine-induced apoptosis in 
pancreatic cancer cells involves caspase-8 activation and persistent activation of JNK. 
Members of the Bcl-2 family are also involved in the regulation of cell death 
induced by ER stress (Oakes et al., 2006). In normal conditions, mammalian cells 
express low levels of Bax, which is predominantly a soluble monomeric protein in the 
cytosol (Hsu et al., 1997). Under ER stress conditions, a significant fraction of Bax may 
translocate from cytosol to membrane fractions, in particular the mitochondrial 
membrane (Hsu et al., 1997). Insertion of Bax into mitochondria causes the release of 
cytochrome c and Ca2+ to the cytosol. Our previous (Mollinedo et al., 1997; Nieto-
Miguel et al., 2007) and present data indicate that edelfosine does not modify the 
expression of antiapoptotic Bcl-2 and Bcl-XL genes, whereas Bax is activated. In 
addition, cells lacking both Bax and Bak have been shown resistant to ER stress-
induced apoptosis (Zong et al., 2001). We have previously reported that bax-/-/bak-/- 
double-knockout cells fail to undergo edelfosine-induced ER-stored Ca2+ release and 
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apoptosis (Nieto-Miguel et al., 2007). Taken together, our previous and present results 
suggest a role for Bax in edelfosine-induced apoptosis in pancreatic cancer cells. 
Overall, the results reported here indicate that edelfosine exerts its proapoptotic 
action in pancreatic cancer cells, both in vitro and in vivo, through its accumulation in 
the ER that leads to a sustained ER stress, and eventually to cell death. These data 
suggest that ER targeting by edelfosine may represent a promising new framework in 
the treatment of currently incurable pancreatic cancer. Our results also provide a 
rationale for searching new effective agents targeting ER to treat pancreatic cancer. 
 
Materials and methods 
Reagents  
Detailed information on the reagents used is included in Supplementary data. 
 
Cell culture  
Detailed information on the cell lines used is included in Supplementary data. 
 
bcl-xL transfection   
BxPC-3 cells (1-2 X 105) were transfected with 8 μg of pSFFV-Neo or pSFFV-bcl-xL 
expression vector as previously described (Mollinedo et al., 1997), using Lipofectin 
reagent (Life Technologies, Carlsbad, CA). Transfected clones were selected by 
growth in the presence of 600 μg/ml of G418 (Sigma), and then cultured at 250 μg/ml 
of G418, and monitored by Western blotting using the 2H12 anti-29 kDa Bcl-XL 
monoclonal antibody (BD Biosciences Pharmingen, San Diego, CA). 
 
Edelfosine uptake  
Drug uptake was measured as previously described (Mollinedo et al., 1997) with slight 
modifications. After incubating 106/ml cells with 10 μM edelfosine plus 0.05 μCi/ml 
[3H]edelfosine for 1 h, and subsequent exhaustive washing (five times) with 1% BSA-
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PBS, 0.1 ml of 0.2% Triton X-100 was added to the cell pellets, and the incorporated 
radioactivity was counted on a beta-counter by mixing with water-miscible liquid 
scintillation cocktail. [3H]edelfosine (specific activity, 42 Ci/mmol) was synthesized by 
tritiation of the 9-octadecenyl derivative (Amersham Buchler, Braunschweig, Germany). 
 
Drug subcellular localization 
The subcellular localization of edelfosine in pancreatic cancer cells was examined with 
the newly synthesized edelfosine fluorescent analog 1-O-[11’-(6’’-ethyl-1’’,3’’,5’’,7’’-
tetramethyl-4’’,4’’-difluoro-4’’-bora-3a’’,4a’’-diaza-s-indacen-2’’-yl)undecyl]-2-O-methyl-
rac-glycero-3-phosphocholine (Et-BDP-ET) (Mollinedo et al., 2011), a kind gift from F. 
Amat-Guerri and A. U. Acuña (Consejo Superior de Investigaciones Científicas, 
Madrid, Spain). ER was visualized by transfecting cells with 4 μg of a plasmid encoding 
endoplasmic reticulum-targeted red fluorescence protein (erRFP) (Klee and Pimentel-
Muinos, 2005), kindly provided by F. X. Pimentel-Muinos (Instituto de Biología 
Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Salamanca, 
Spain). Detailed information on the conditions used in this study is included in 
Supplementary data. 
 
Apoptosis assay 
Quantitation of apoptotic cells was determined by flow cytometry as the percentage of 
cells in the sub-G1 region (hypodiploidy) in cell cycle analysis as previously described 
(Gajate et al., 2000b). 
 
[Ca2+]ER measurements with aequorin 
BxPc-3 cells were transiently transfected with ER-targeted mutated aequorin (Alvarez 
and Montero, 2002; Montero et al., 1997a). The cells were plated onto 13-mm round 
coverslips. Before reconstituting aequorin, [Ca2+]ER was reduced by incubating the cells 
for 5-10 min at room temperature with the sarcoplasmic and endoplasmic reticulum 
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Ca2+-ATPase inhibitor 2,5-di-tert-buthyl-benzohydroquinone (BHQ) (10 µM) in standard 
external medium containing: 145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM glucose, 
10 mM HEPES, pH 7.4, supplemented with 3 mM EGTA. Cells were then incubated for 
90 min at room temperature in standard medium containing 0.5 mM EGTA, 10 µM BHQ 
and 2 µM coelenterazine n. The coverslip was then placed in the perfusion chamber of 
a purpose-built thermostatized luminometer, and standard medium containing 1 mM 
Ca2+ was perfused to refill the ER with Ca2+.  Calibration of the luminescence data into 
[Ca2+] was made using an algorithm as previously described (Alvarez and Montero, 
2002). 
 
Western blot 
Cells (4-5 X 106) were lysed with 60 μl of 25 mM Hepes (pH 7.7), 0.3 M NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.1 % Triton X-100, 20 mM β-glycerophosphate, 0.1 mM sodium 
orthovanadate, supplemented with protease inhibitors (1 mM phenylmethylsulfonyl 
fluoride, 20 µg/ml aprotinin, 20 µg/ml leupeptin). Proteins (45 µg) were run on SDS-
polyacrylamide gels, transferred to nitrocellulose filters, blocked with 5% (w/v) defatted 
powder milk in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 0.1% Tween 20 (TBST) for 
60 min at room temperature, and then incubated for 1 h at room temperature or 
overnight at 4ºC with specific antibodies. Detailed information on the antibodies used is 
included in Supplementary data.  
 
Mitochondrial cytochrome c release measurement 
Release of cytochrome c from mitochondria to cytosol was analyzed by Western blot 
as previously described (Gajate and Mollinedo, 2001; Pique et al., 2000). 
 
Solid phase JNK assay 
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Protein kinase assays were carried out using a fusion protein between glutathione S-
transferase and c-Jun (amino acids 1-223) as a substrate of JNK, as previously 
described (Gajate et al., 2000a; Gajate et al., 1998).    
 
Reverse transcriptase-polymerase chain reaction (RT-PCR) and restriction analysis 
Detailed information on the conditions for RT-PCR and primer sequences are included 
in Supplementary data. Subsequent PstI restriction analysis of the XBP1 amplicon was 
carried out following standard procedures.   
 
Xenograft mouse models 
Eight-week-old female CB17-SCID mice (Charles River Laboratories, Lyon, France), 
kept and handled according to institutional guidelines, complying with Spanish 
legislation under 12/12 h light/dark cycle at a temperature of 22ºC, received a standard 
diet and acidified water ad libitum. Capan-2 and HuP-T4 cells (5 x 106) were injected 
subcutaneously in 100 μl PBS together with 100 μl Matrigel basement membrane 
matrix (Becton Dickinson, Franklin Lakes, NJ) into the right flank of each mouse. When 
tumors were palpable, approximately 2 weeks after tumor cell implantation, mice were 
randomly assigned to cohorts of 8 mice each, receiving a daily oral administration of 
edelfosine (30 mg/kg of body weight) or an equal volume of vehicle (water). The 
shortest and longest diameter of the tumor were measured with calipers at the 
indicated time intervals, and tumor volume (mm3) was calculated using the following 
standard formula: (the shortest diameter)2 x (the longest diameter) x 0.5. Animal body 
weight and any sign of morbidity were monitored. Drug treatment lasted 32 days for 
Capan-2-bearing mice, and 47 days for HuP-T4-bearing mice. Animals were killed 24 h 
after the last drug administration according to institutional guidelines, and tumors were 
carefully removed, weighed, and analyzed. A necropsy analysis involving tumors and 
distinct organs was carried out.  
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TUNEL assay in tumor sections 
The DeadEndTM Fluorometric TUNEL System (Promega, Madison, WI) was used to 
detect apoptosis. Detailed information on the conditions used in this study is included in 
Supplementary data. 
 
Immunohistochemistry  
Tumor tissue samples were fixed in 4% buffered paraformaldehyde and embedded in 
paraffin. Detailed information on the conditions used in this study is included in 
Supplementary data. 
 
Statistical analysis 
The results given are the mean ± standard deviation (SD) of the number of 
experiments indicated. Statistical evaluation was performed by Student’s t-test. A P-
value of < 0.05 was considered statistically significant.  
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Figure legends 
 
Figure 1 Induction of apoptosis by edelfosine and structurally related compounds, and 
edelfosine uptake, in human pancreatic cancer cell lines. (a) Cells were incubated in 
the absence (Control) or in the presence of 10-20 μM edelfosine (EDLF) for the 
indicated times, and apoptosis was analyzed. (b) Cells untreated (Control) or treated 
with different alkyl-lysophospholipid analogues (20 μM) for the indicated times, were 
analyzed for apoptosis. (c) EDLF uptake in different pancreatic cancer cells. 106 
cells/ml were incubated with 10 μM edelfosine + 0.05 μCi/ml [3H]edelfosine for 1 h, and 
then cells were exhaustively washed (five times) with 1% BSA-PBS to remove the drug 
loosely bound to the external side of the cell membrane, and edelfosine uptake was 
determined by measuring incorporated radioactivity. Data shown are means ± SD of 
three independent experiments. 
 
Figure 2 ER drug localization and ER stress in edelfosine-treated pancreatic tumor 
cells. (a) HuP-T4 and Capan-2 cells were transfected with erRFP plasmid to visualize 
ER (red fluorescence) and then incubated with Et-BDP-ET (green fluorescence). Cells 
were also stained for nuclei with DAPI (blue fluorescence). Areas of colocalization 
between ER and Et-BDP-ET in the merge panels are yellow. The corresponding 
differential interference contrast (DIC) microscopy images are also shown. (b) HuP-T4 
cells, untreated (C) or treated with 20 μM edelfosine for the indicated times, were 
analyzed by Western blot using specific antibodies for the indicated proteins. β-Actin 
was used as a loading control. (c) Cells untreated (C) or treated with 20 μM EDLF for 
different times were analyzed for JNK activation. The migration position of GST-c-Jun-
1-223 is indicated. Cells untreated (Control) or pre-treated with caspase-4 inhibitor z-
LEVD-fmk (d) or JNK inhibitor SP600125 (BxPC-3 cells) (e) for 1 h, and then incubated 
without or with 20 μM EDLF for 48 h, were analyzed for apoptosis. (f) Cells were 
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incubated without (C) or with edelfosine for the indicated times, and then total RNA was 
isolated and subjected to RT-PCR using specific primers for the XBP1 gene. The 
positions of the amplification products uXBP1 and sXBP1 are indicated. PCR 
amplification of β-actin was used as an internal control. Data shown are means ± SD or 
representative experiments of three performed.  
 
Figure 3 Edelfosine-mediated changes in [Ca2+]ER in BxPC-3 cells. (a) Effect of 
edelfosine on ER calcium uptake. Cells were reconstituted with coelenterazine n, and 
then medium containing 1 mM Ca2+ was perfused as indicated. When a steady state 
was obtained, 10 µM edelfosine was added to the calcium containing medium. The 
trace shown is the mean of 5 different experiments. (b) Effect of preincubation with 
edelfosine on ER calcium refilling. Cells were reconstituted with coelenterazine n either 
in the presence of 10 µM edelfosine for the indicated times. Then 1 mM Ca2+ was 
perfused as indicated. Traces are the means of 7 (15 min), 3 (30 min) and 6 (60 min) 
different experiments. 
 
Figure 4 Caspase-8/10 activation and Bid cleavage in edelfosine-treated pancreatic 
cancer cells. (a) Cells untreated (C) or treated with 20 μM edelfosine for the indicated 
times, were assayed for caspase-8 and caspase-10 activation by Western blot. (b) 
Cells untreated (Control) or pre-treated with caspase inhibitors z-IETD-fmk or z-AEVD-
fmk for 1 h, and then incubated without or with 20 µM edelfosine (EDLF) for 48 h, were 
analyzed for apoptosis. (c) Time-course of Bid cleavage in cells untreated (C) or 
treated with 20 µM edelfosine. β-Actin was used as a loading control. Data shown are 
means ± SD or representative experiments of three performed. 
 
Figure 5 Mitochondrial and caspase involvement in edelfosine-induced apoptosis in 
pancreatic cancer cells. (a) Cells were untreated (C) or treated with 20 μM edelfosine 
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for the indicated times, and cleavage of caspase-9, -3, -7, and PARP was detected by 
Western blotting. β-Actin was used as a loading control. (b) Cells pre-incubated without 
(Control) or with caspase inhibitors z-LEHD-fmk, Ac-DEVD-CHO and z-VAD-fmk for 1 
h, and then treated without or with 20 μM edelfosine (EDLF) for 48 h, were analyzed for 
apoptosis. (c) BxPC-3 cells were untreated (C) or treated with 20 μM edelfosine at the 
indicated times, and cytochrome c (Cyt c), β-actin, and cytochrome c oxidase subunit II 
(cyt c Ox. II) were analyzed in the cytosolic and mitochondrial fractions by Western 
blot. β-Actin and cytochrome c oxidase subunit II were used as controls for cytosolic 
and mitochondrial proteins, respectively, that do not relocate to other subcellular 
locations during treatment. (d) Cell lysates from Neo (BxPC-3-Neo) and Bcl-XL (BxPC-
3-Bcl-XL) transfected BxPC-3 cells were subjected to immunoblotting and analyzed for 
the expression of Bcl-XL protein. (e) BxPC-3-Neo and BxPC-3-Bcl-XL cells were 
incubated for the indicated times without (Control) or with 20 μM edelfosine, and 
apoptosis was quantitated. (f) Western blot analysis of mitochondrial cytochrome c (Cyt 
c) release into the cytosolic fraction (CYT) in BxPC-3-Neo and BxPC-3-Bcl-XL cells. 
Cytochrome c oxidase subunit II (cyt c Ox. II) in the mitochondrial fraction (MIT) was 
used as a control of the amount of mitochondria used in the experiment. Data shown 
are means ± SD or representative experiments of three performed. 
 
Figure 6 Antitumor effect of edelfosine on human pancreatic cancer xenograft models. 
(a) CB17-SCID mice were inoculated subcutaneously with Capan-2 or HuP-T4 cells. 
Oral administration of edelfosine (30 mg/kg, once-daily dosing regimen) and water 
vehicle (Control) started after the development of a palpable tumor in tumor-bearing 
mice in parallel (n = 8). Caliper measurements of each tumor were carried out at the 
indicated times. Edelfosine (EDLF) inhibited significantly pancreatic tumor growth 
compared with the vehicle-treated control group (P < 0.05, between drug-treated and 
drug-free control mice; from days 9 and 18 of treatment in Capan-2- and HuP-T4-
 31
bearing mice until the end of the experiments). Data shown in panel A are means ± SD 
(n = 8). (b) After completion of the in vivo assays, control and EDLF-treated mice were 
sacrificed and tumor weight and volume were measured. Average tumor size and 
weight values of each experimental group are shown. * indicates values that are 
statistically significant between drug-treated and drug-free control mice at P < 0.05. (c) 
A remarkable pancreatic tumor growth inhibition was observed after 32 and 47 days of 
edelfosine treatment in Capan-2- and HuP-T4-bearing SCID mice. Representative 
tumors isolated from drug-free pancreatic-bearing mice (Control) and drug-treated 
pancreatic tumor-bearing mice (EDLF) are shown.  
 
Figure 7 Edelfosine induces apoptosis and CHOP/GADD153 expression in pancreatic 
xenograft tumor. (a) Microscopic view of the paraffin section of a human Capan-2 
tumor xenograft stained with H&E from control drug-free and edelfosine-treated mice 
(400x magnification). Tissue sections of tumors from edelfosine-treated mice show the 
presence of irregular and medium-sized giant cells with eosinophilic cytoplasm (arrow), 
cells with pyknotic nuclei (asterisk), and apoptotic bodies characteristic of cell death by 
apoptosis (arrowhead). These alterations are not seen in the cancer cell morphology 
from drug-free control Capan-2 tumors. (b) Sections of Capan-2-bearing mice from 
control or edelfosine-treated were assayed for apoptosis by TUNEL staining. FITC-
TUNEL reaction (FITC, green fluorescence) stains apoptotic nuclei. Propidium iodide 
(PI, red fluorescence) stains DNA in the whole cell population. Areas of colocalization 
between FITC-TUNEL and PI in the merge panels are yellow. The corresponding DIC 
microscopy images are also shown. (c) Treatment of Capan-2 tumor-bearing mice with 
edelfosine results in increased tumor apoptosis as detected by activated caspase-3 
staining. Cleaved caspase-3-negative cells were shown in untreated mice (Control), 
whereas cleaved caspase-3-positive cells (arrows) were observed in edelfosine-treated 
mice. (d) Representative sections obtained from Capan-2-xenograft tumor tissues were 
stained for CHOP/GADD153. Positive staining is shown as dark blue coloring of the 
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nucleus of the cells (arrows) in the edelfosine-treated tumor. Apoptotic cells, caspase-3 
positive staining, and CHOP/GADD153 staining in tumor tissues were scored as 
described in Supplementary data. Images shown are representative of three 
independent experiments. 
 
Figure 8 Schematic model of ER involvement in edelfosine-induced apoptosis in 
pancreatic cancer cells. This is a schematic diagram designed to portray one currently 
plausible mechanism of how edelfosine induces apoptosis via ER stress in pancreatic 
tumor cells. Edelfosine is incorporated into the tumor cell and accumulates in the ER, 
generating an ER stress response that leads to cell death. See text for details. 
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Figure 1 - Gajate et al. 
Figure 2 - Gajate et al. 
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Figure 3 - Gajate et al. 
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Figure 4 - Gajate et al. 
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Figure 5 - Gajate et al. 
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Figure 6 - Gajate et al. 
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Figure 8 - Gajate et al. 
 
 
 
 
 
